

---

## WilmerHale Reps Disarm Therapeutics in \$30M Series A Financing

OCTOBER 5, 2017

On September 19, 2017, Disarm Therapeutics, a new biotechnology company developing therapeutics to treat patients with neurological diseases by preventing axonal degeneration, announced the recent completion of a \$30 million Series A financing. The round was led by Atlas Venture, with co-investors Lightstone Ventures and AbbVie Ventures. Disarm was co-founded, seeded and incubated in 2016 by Atlas Venture, together with Dr. Jeffrey Milbrandt and Dr. Aaron DiAntonio of Washington University in St. Louis.

[Stuart Falber](#) led the WilmerHale team representing Disarm in this transaction, which also included [Stephanie Singer](#) and [Brett Bromann](#).

[Read Disarm's press release](#) for more information.